Gene Expression and Cancer Group - VHIO

Vall d'Hebron Institute of Oncology (VHIO) on X: 📣 New VHIO – @CaixaResearch Scientific Seminars @FundlaCaixa❗️ 👨‍🔬 Ramon Alemany, @ICO_oncologia @idibell_cat 🔹 Cancer Virotherapy. Oncolytic Adenoviruses 🗓 Friday, 2nd June, 12 pm

Cancer Genomics Group Archives - VHIO

Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple‐negative breast cancer

Cancer Computational Biology Group - VHIO

MYC inhibition in melanoma: Preclinical promise and the unveiling of a prognostic gene signature

Prognostic Significance of Progesterone Receptor–Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer

VIGex Could Guide Patient Selection for Personalized Immunotherapy

Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancer - Frigola - 2021 - Molecular Oncology - Wiley Online Library

Cancer Genomics Group - VHIO

Ana Vivancos Prellezo on LinkedIn: Ref. 76-2023 Post-doctoral Scientist ( Cancer Genomics Lab) - VHIO

The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers

Malumbres Lab (@MalumbresLab) / X

The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates